Paper Details

  1. Home
  2. Paper Details

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Author: BarriosCarlos, CrinòLucio, FrankeFabio Andre, GrinstedLynda, JeanninGaëlle, JännePasi A, PereiraJosé Rodrigues, ShawAlice T, SmithIan, SmithPaul, VansteenkisteJohan, ZazulinaVictoria

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Selumetinib is a drug that blocks MEK1/MEK2, a protein involved in cancer growth, and may be effective in treating KRAS-mutant lung cancer. This study is a phase 2 trial evaluating the combination of selumetinib and docetaxel in patients with advanced KRAS-mutant lung cancer.
Paper Details　
Original Abstract of the Article :
No targeted therapies are available for KRAS-mutant non-small-cell lung cancer (NSCLC). Selumetinib is an inhibitor of MEK1/MEK2, downstream of KRAS, with preclinical evidence of synergistic activity with docetaxel in KRAS-mutant cancers. We did a prospective, randomised, phase 2 trial to assess sel...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1470-2045(12)70489-8

データ提供：米国国立医学図書館（NLM）

Combating KRAS-Mutant Lung Cancer: A New Treatment Strategy

The battle against lung cancer is an ongoing one. Like a desert wanderer, researchers are constantly seeking new weapons to combat this formidable foe. This study focuses on KRAS-mutant non-small-cell lung cancer (NSCLC), a particularly aggressive form of the disease. The researchers investigated the potential of a combination therapy using selumetinib, a MEK1/MEK2 inhibitor, and docetaxel. This combination therapy, like a caravan with multiple resources, aimed to target KRAS-mutant cancers.

A Promising Approach for KRAS-Mutant Lung Cancer

The results of this phase 2 trial showed promising signs for patients with previously treated KRAS-mutant NSCLC. The researchers observed a positive response to the selumetinib plus docetaxel treatment, suggesting that this combination therapy may offer a new avenue for treating this aggressive form of lung cancer. This study offers a glimmer of hope in the fight against this disease, much like finding a spring in a barren desert.

Navigating the Sands of Lung Cancer Treatment

This research opens up new possibilities for treating KRAS-mutant lung cancer, a type of lung cancer that has proven particularly challenging to treat. This study, like a compass guiding a traveler through the desert, offers a new direction for tackling this formidable disease. It's crucial to remember that further research is needed to fully understand the long-term effectiveness and safety of this combination therapy.

Dr. Camel's Conclusion

This research explores a promising new approach for treating KRAS-mutant lung cancer, a disease that has been particularly difficult to conquer. Like a well-traveled merchant seeking a new trade route, this study offers a potential solution for patients with this aggressive form of lung cancer. While further research is needed to fully understand the long-term implications of this therapy, it offers a glimmer of hope in the ongoing battle against lung cancer.

Date :
  1. Date Completed 2013-04-03
  2. Date Revised 2022-04-16
Further Info :

Pubmed ID

23200175

DOI: Digital Object Identifier

10.1016/S1470-2045(12)70489-8

Related Literature

Article Analysis
・Side Effects of selumetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.